• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EVP & Chief HR Officer Craig Ryan R was granted 970 shares, increasing direct ownership by 22% to 5,353 units (SEC Form 4)

    9/4/25 11:53:06 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Craig Ryan R

    (Last) (First) (Middle)
    220 VIRGINIA AVEUNE

    (Street)
    INDIANAPOLIS IN 46204

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Elevance Health, Inc. [ ELV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & Chief HR Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/02/2025 A 970(1) A $0 5,353 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) $322.33 09/02/2025 A 3,690 (2) 09/02/2035 Common Stock 3,690 $0 3,690 D
    Explanation of Responses:
    1. Represents restricted share units. Restrictions lapse as follows: 323 shares each on 9/2/2026 and 9/2/2027, and 324 shares on 9/2/2028.
    2. The option represents a right to purchase a total of 3,690 shares, and is exercisable in three annual installments of 1,230 shares, beginning on 9/2/2026, which is the one-year anniversary of the option grant date.
    Remarks:
    /s/ Kathleen S. Kiefer, Attorney in fact 09/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reflects On The Changed Role of Health Plans

    By simplifying the healthcare experience, improving care coordination, and leveraging data-driven insights, Elevance Health affiliated health plans help members navigate a range of healthcare experiences with greater confidence As 2025 draws to a close, Elevance Health highlights how today's health plans are evolving to better support their members in a broader range of situations that affect health, including cancer diagnoses, mental health crises, and unexpected health concerns during pregnancy. From employer-sponsored health insurance to government-sponsored programs, health plans are evolving to better support their members in a broader range of situations that affect health. In partne

    12/12/25 2:00:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"

    12/12/25 11:10:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Craig Ryan R claimed ownership of 3,341 shares (SEC Form 3)

    3/A - Elevance Health, Inc. (0001156039) (Issuer)

    11/21/25 4:17:27 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & CFO Kaye Mark covered exercise/tax liability with 2,895 shares, decreasing direct ownership by 15% to 16,082 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    10/3/25 4:17:15 PM ET
    $ELV
    Medical Specialities
    Health Care

    EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 152 shares, decreasing direct ownership by 3% to 5,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    9/5/25 4:21:42 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    Elevance Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    12/10/25 4:35:16 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    11/10/25 5:03:08 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    10/21/25 11:11:08 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Elevance Health

    Goldman initiated coverage of Elevance Health with a rating of Neutral

    10/14/25 8:49:08 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Argus

    Argus downgraded Elevance Health from Buy to Hold

    7/21/25 8:26:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00

    7/18/25 8:10:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

    Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

    10/30/24 12:55:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"

    12/12/25 11:10:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports Third Quarter 2025 Results

    Executing with discipline to improve affordability and elevate the member experience 3Q 2025 operating revenue of $50.1 billion, up 12.0% from 3Q 2024 3Q 2025 diluted EPS1 of $5.32; adjusted diluted EPS2 of $6.03 Reaffirm FY 2025 benefit expense ratio and adjusted diluted EPS guidance of approximately 90.0% and approximately $30.00, respectively Returned $3.3 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported third quarter 2025 results. "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we're focused on advancing affordability and ele

    10/21/25 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2025 Results on October 21

    Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 21, 2025, until the end of the day on November 21, 2025. Th

    9/29/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care